Restructuring for Recovery in a Competitive Musculoskeletal Market

Zimmer Biomet Holdings is a global leader in musculoskeletal healthcare, designing, manufacturing, and marketing orthopedic products and surgical solutions. The company was formed in 2015 through the merger of Zimmer Holdings and Biomet, creating one of the world's largest pure-play orthopedic device companies.

The company generates revenue across three primary segments: Knees (approximately 30% of revenue), Hips (approximately 25%), and Sports Medicine, Extremities, Trauma & Craniomaxillofacial (approximately 20%), with the remainder coming from Dental, Spine, and other surgical products. Zimmer Biomet sells primarily to hospitals, ambulatory surgery centers, and healthcare systems, with the U.S. representing roughly 55–60% of total sales and international markets comprising the balance.

With annual revenue of approximately $7.5B and over 18,000 employees worldwide, Zimmer Biomet serves customers in more than 100 countries. The company's competitive advantage lies in its comprehensive product portfolio spanning the full continuum of musculoskeletal care, from fracture repair to complex revision arthroplasty, coupled with its ROSA robotic platform that positions it in the rapidly digitizing surgical landscape.

Near-Term (2026–2027): The company is navigating a period of procedure-volume normalization following the post-COVID surge. We expect low-single-digit organic revenue growth in 2026, accelerating modestly in 2027 as new product launches gain traction. Key near-term drivers include the continued rollout of the ROSA Knee and ROSA Hip robotic systems, expansion of the Persona knee system into international markets, and recovery in elective procedure volumes as staffing constraints at hospitals ease. The company's recent regulatory approvals in China and Japan for several key platforms should also contribute incremental growth beginning in late 2026.

Medium-Term (2028–2029): We project 4–6% organic revenue growth as the benefits of the company's R&D pipeline—particularly in the extremities and sports medicine categories—begin to scale. The global adoption of robotic-assisted surgery remains in early innings, with penetration rates below 15% in major markets. Zimmer Biomet's open-architecture approach, which allows ROSA to integrate with any implant system, positions it to capture share from competitors with closed ecosystems. Additionally, the expansion of outpatient joint replacement procedures, which now account for over 30% of U.S. knee replacements, favors companies with ambulatory surgical center-focused commercial models and streamlined product portfolios.

Revenue growth has decelerated from the post-COVID rebound as the company lapped strong prior-year comparisons and faced ongoing supply chain disruptions. However, the margin picture is more encouraging: restructuring savings, favorable product mix shifts toward higher-margin extremities and sports medicine, and manufacturing footprint optimization are driving consistent operating margin expansion. We expect gross margins to recover toward 70% as supply chain costs normalize and the company realizes procurement savings from its supplier consolidation program.

EPS growth is projected to outpace revenue growth by a wide margin, reflecting the operating leverage inherent in the restructuring program. The company's GAAP EPS of $4.12 in 2025 already reflects meaningful restructuring charges; adjusted EPS, which excludes these one-time items, is approximately 15–20% higher. Our projections assume continued share repurchases funded by free cash flow, contributing roughly 1–2% annual EPS accretion.

The global musculoskeletal device market is valued at approximately $60B and is projected to grow 4–5% annually through 2030, driven by aging demographics, rising obesity rates, and expanding access to surgical care in emerging markets. Joint replacement represents the largest category at roughly $25B, followed by spine ($12B), trauma ($8B), and sports medicine ($7B).

Zimmer Biomet holds the #1 position in knees globally and #2 in hips, with estimated market shares of 25% and 20%, respectively. The competitive landscape is concentrated among four major players who collectively control approximately 80% of the large-joint market:

The competitive battleground has shifted from implant design to enabling technologies, particularly robotics and digital surgery. Stryker's Mako platform has been the market leader, with over 2,000 systems installed globally. Zimmer Biomet's ROSA platform, with approximately 700 installations, is gaining traction, particularly given its open architecture that works with any implant. The company's Persona knee system remains a top-tier product with strong surgeon loyalty, providing a defensive moat against competitive inroads.

Discounted Cash Flow Analysis: We employ a three-stage DCF model with the following assumptions: revenue growing at 5% annually through 2033 (reflecting the company's medium-term outlook), operating margins expanding to 22% by 2030 as restructuring benefits fully materialize, a terminal growth rate of 2.5%, and a weighted average cost of capital of 8.5% (reflecting the company's 0.47 beta, a 4.5% equity risk premium, and a 4.0% risk-free rate). This analysis yields an intrinsic value of approximately $110 per share, implying roughly 18% upside from the current price of $92.80.

Comparable Company Analysis: ZBH trades at a significant discount to its med-tech peers on every multiple:

The valuation gap is attributable to ZBH's slower growth trajectory and execution risk around its restructuring. However, as the company demonstrates consistent margin improvement and reaccelerating revenue growth, we expect multiple expansion toward the peer average. Our 12-month price target of $105 represents approximately 15x forward earnings, a still-conservative discount to peers that we believe is achievable given the company's improving fundamentals.

• Elective Procedure Volume Volatility: Joint replacement procedures are elective and deferrable. Economic downturns, hospital staffing shortages, or shifts in patient preferences toward conservative care could delay procedures, reducing revenue and pressuring margins. The company's 2025 performance demonstrated vulnerability to procedure-volume softness.
• Competitive Share Loss: Stryker's Mako robotics platform continues to gain share in the knee market, and Johnson & Johnson's VELYS system is rapidly expanding. If Zimmer Biomet fails to differentiate its ROSA platform or loses surgeon loyalty on its core implant systems, market share erosion could persist and undermine the growth assumptions in our model.
• Restructuring Execution Risk: The company's margin expansion thesis depends on successful execution of its manufacturing consolidation and supply chain optimization programs. These initiatives carry operational disruption risk, potential product supply interruptions, and the possibility that cost savings fall short of targets. Historical med-tech restructurings have frequently encountered implementation delays.
• Regulatory and Reimbursement Pressures: Ongoing scrutiny of device pricing in the U.S. and Europe could pressure reimbursement rates. Additionally, the FDA's evolving regulatory framework for software-enabled devices, including robotic systems, creates approval timeline uncertainty. Any adverse regulatory developments could delay product launches and dampen growth.
• Currency and Geopolitical Exposure: With 40–45% of revenue generated internationally, the company faces meaningful foreign exchange translation risk. Additionally, escalating trade tensions, particularly between the U.S. and China, could disrupt supply chains or limit market access in key growth regions.